With regulatory decisions approaching for satralizumab, Roche has presented long-term data which the company claims reinforce the safety of its investigational neuromyelitis optica spectrum disorder (NMOSD) drug.
The Swiss major has presented pooled safety results at the European Academy of Neurology (EAN) meeting from the SAkuraStar and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
